In a significant development for the biopharmaceutical landscape, AusperBio has successfully raised $10 million to further advance its cutting-edge research and development initiatives. As a clinical-stage company operating in both the USA and China, AusperBio is at the forefront of innovation with its proprietary Med-Oligo™ ASO platform, which aims to revolutionize the treatment landscape for chronic hepatitis B and other complex medical conditions. This funding will enable the company to enhance its oligonucleotide and targeted delivery technologies, building upon its novel insights into Antisense Oligonucleotide (ASO) design. With the capability to substantially improve current ASO therapeutics, the Med-Oligo™ platform is poised to empower the treatment of a wide array of ailments, including viral infections, metabolic conditions, genetic disorders, and immune diseases. The infusion of capital will accelerate AusperBio’s commitment to developing transformative therapies that address unmet medical needs, ultimately bringing hope to patients around the world. “This funding is a crucial step in our mission to innovate therapies that can make a lasting difference in patients’ lives,” said a representative from AusperBio. With an eye towards expanding its capabilities and product pipeline, AusperBio is set to continue its impactful journey in the biopharmaceutical sector, leveraging advanced science to tackle some of today’s most challenging health issues. The future looks bright as AusperBio aims to set new standards in therapeutic development and improve health outcomes globally.
Tracer Bio Secures $10 Million in Series A Funding to Advance Transformative Therapies for Hepatitis B and Beyond
Recently funded · $10.0M Series aBiopharmaceutical
Get the full Tracer Bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
